BioSpace News Archive

Pharm Country

Amicus Therapeutics Launches Galafold (Migalastat) for Treatment of Fabry Disease in Spain

Galafold is designed to restore alpha-Gal A activity in patients who have amenable mutations (an estimated 35% to 50% of the Fabry population).

January 18, 2018
·
7 min read
Pharm Country

Tauriga Sciences Actively Evaluating Potential Blockchain Opportunities

There can be no guarantees that the Company will determine that any of the potential opportunity under evaluation is worthy of acquisition or investment.

January 18, 2018
·
3 min read
Business

SPINEWAY : 2017 Revenue Was an Historic Year: €9.1M (+97%)

2017 was an epicyear for SPINEWAY.

January 18, 2018
·
1 min read
Business

NeuroMetrix Announces Date for Fourth Quarter and Full Year 2017 Financial Results Conference Call

The Company will host a conference call at 8:00 a.m., Eastern Time on January 25, 2018 to discuss its financial results as well as business developments affecting the Company.

January 18, 2018
·
1 min read
Business

Immatics Appoints Thomas Ulmer as CFO

Thomas joins Immatics from the Merck Group, where he is currently CFO of the Allergopharma Business Unit.

January 18, 2018
·
1 min read
Business

Former FDA Regulatory Scientist Joins Pearl Pathways

Pearl Pathways announces the hiring of Robert Seevers, PhD as Senior Advisor to serve biopharmaceutical companies.

January 18, 2018
·
3 min read
Business

New Global Leaders Join CDISC Board of Directors

The Clinical Data Interchange Standards Consortium (CDISC) today announced Chris Decker and Pam Howard have joined its Board of Directors to serve three-year terms, which began 1 January 2018.

January 18, 2018
·
3 min read
Relevium to Host Webcast to Discuss Previously Announced Blockchain Project

Relevium announce that it will be hosting a webcast in conjunction with Quantomic LLC to discuss Tagspire, the virtual intelligent e-retail platform and artificial intelligence technology stack.

January 18, 2018
·
6 min read
Policy

European Commission Approves Amgen and Allergan’s Mvasi (Biosimilar Bevacizumab) for the Treatment of Certain Types of Cancer

The EC approved MVASI based on a comprehensive data package that demonstrated MVASI and bevacizumab are highly similar, with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products.

January 18, 2018
·
20 min read
Policy

Statement From FDA Commissioner Scott Gottlieb, M.D., on New Policy Steps for Strengthening Public Warning and Notification of Recalls

Americans depend on the U.S. Food and Drug Administration to help ensure that the products they buy are safe.

January 18, 2018
·
4 min read